Zealand Pharma — November 2023
-
Her lidt næring til drømmene hen over weekenden
-
In an interview with Reuters, Novo Nordisk's CEO Lars Fruergaard Jorgensen said the company wants to buy more companies with drugs in the early- to mid-stages of development through "bolt-on" deals of up to a few billion dollars.
-
"So diabetes, obesity, cardiovascular disease, the whole cardiometabolic space, but also in the rare blood disorders, hemophilia, sickle cell, we believe that we have a stronghold there," Jorgensen said in an interview.
-
Novo Nordisk Seeks Obesity, Diabetes 'Bolt-On' Deals As It Beefs Up Capacity To Meet Soaring Demand - Nov
Novo Nordisk A/S (NYSE: NVO) plans to invest more than DKK 42 billion
Benzinga (www.benzinga.com)
-
Godmorgen
-
Godmorgen. Spørgsmål til Q&A er meget velkommen.
-
God morgen
Og Helge - Du skal få spørgsmål til Q&A -
Du skriver dem ind og poster i Q&A-chatten som du finder i dropdown. Tilmeld dig her https://www.proinvestor.com/index.php?p=q-and-a&groupid=165
-
Tak Eliot.:-)
-
Kunne du se hvor meget fra Novo Nordisk?
-
Jeg skal prøve at komme nøje igennem hele regnskabet men det bliver først om et par dage og hvis du allerede kender tallet så lad os få det på bordet.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind